Chemotherapy in patients with recurrent and progressive central neurocytoma

Alba A. Brandes, Pietro Amistà, Marina Gardiman, Lorenzo Volpin, Daniela Danieli, Bianca Guglielmi, Carla Carollo, Gianpietro Pinna, Sergio Turazzi, Silvio Monfardini

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND. Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available. METHODS. Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m2/day, for 4 days; cisplatin, 25 mg/m2/day, for 4 days; and cyclophosphamide, 1000 mg/m2, on Day 4; this cycle was repeated every 4 weeks. RESULTS. Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively. CONCLUSIONS. In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalCancer
Volume88
Issue number1
DOIs
Publication statusPublished - Jan 1 2000

Keywords

  • Central neurocytoma
  • Chemotherapy
  • Recurrent
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Chemotherapy in patients with recurrent and progressive central neurocytoma'. Together they form a unique fingerprint.

Cite this